RxDoctor Payments Data

Than Aung, MD

Internal Medicine · Redding, CANPI 1578504841

Payments from drug & device makers

$16,082in general payments, 2019–2025

Across 871 payments — averaging $18.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Boehringer Ingelheim$2K
  • AstraZeneca$1K
  • Pfizer$1K
  • Lilly USA, LLC$1K
  • Amgen$1K
  • plus $7K from 47 others

What the payments were for

  • Food & beverage$15,83898%
  • Education$2231%
  • Other$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$16,082 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$1,004,958
Medicare patients
1,810
Services billed
11,139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban405$292,216
OzempicSemaglutide144$181,627
FarxigaDapagliflozin Propanediol204$135,148
JardianceEmpagliflozin160$106,738
MounjaroTirzepatide88$91,658
Trelegy ElliptaFluticasone/Umeclidin/Vilanter94$82,852
XareltoRivaroxaban104$72,503
JanuviaSitagliptin Phosphate95$45,090
LinzessLinaclotide75$43,029
RexultiBrexpiprazole54$39,843
ShingrixVaricella-Zoster Ge/As01b/Pf164$36,787
MyrbetriqMirabegron32$27,966
XifaxanRifaximin12$20,432
EntrestoSacubitril/Valsartan49$18,971
NexletolBempedoic Acid16$18,360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,394$292,216405 claims
Novo NordiskOzempic$609$181,627144 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta, Anoro Ellipta$680$150,485312 claims
AstraZenecaFarxiga$1,471$135,148204 claims
Boehringer IngelheimJardiance, Tradjenta$1,531$114,682176 claims
Lilly USA, LLCMounjaro, Trulicity$1,325$104,738102 claims
Johnson & JohnsonXarelto$715$72,503104 claims
AbbVieLinzess, Creon, Synthroid$2,702$68,936219 claims
MerckJanuvia$334$45,09095 claims
Otsuka America Pharmaceutical, Inc.Rexulti$135$39,84354 claims
Astellas Pharma US IncMyrbetriq$438$27,96632 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$88$20,43212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Redding

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →